KZIAKazia Therapeutics Limited American Depositary Shares

ADRCNasdaq (XNAS)·USD

Identity

Security key: 17887
Ticker: KZIA
Type: ADRC — American Depository Receipt Common
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 1999-01-06
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: KZIA

Detail

Enriched 2026-08-14 20:47

Market cap: $146,150,038.21
Shares outstanding (class): 11,335,991
Shares outstanding (weighted): 11,426,899
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 6
Location: NEW SOUTH WALES 2113, C3
Homepage: https://www.kaziatherapeutics.com
Description: Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Market cap and share counts drift.

Funds holding this security

as of 2026-03-31

No reported positions at this date.

Positions are reached through OpenFIGI-resolved ISINs. A security with no resolved ISIN cannot be found this way even if funds do hold it.

Funds holding this security

Identifiers

master.security_identifier

TICKERKZIA
FIGI_COMPOSITEBBG000KC7878
FIGI_SHARE_CLASSBBG001SCPMJ4
CIK0001075880
ISINUS48669G3039
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Kazia Therapeutics is a biopharmaceutical company developing oncology drugs, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.